KA Kineta Bio: Earnings per share for the last twelve months

Official company branding of Kineta, Inc. (KA)

Kineta, Inc. stability is bolstered by outsourcing production to US plants, which eliminates equipment downtime risks; reviewing the 12-month net income per share chart on GURU.Markets, we see that -1.64 describes the current status of the metric. However, geopolitics are hindering international trials, and a revenue shortfall is forcing management to aggressively cut costs to preserve liquidity.

Kineta, Inc. (KA) - Net earnings per share (EPS TTM) from 04/28/2023 to 09/28/2024

Analytical breakdowns and data insights for company Kineta Inc (KA)

- current quotes and average value forecast:
Price Chart Kineta, Inc.|KA - Consensus Target
- company stock capitalization data:
Market Value Kineta, Inc.|KA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value per Share Kineta|KA - Book Capitalization|Market Value to Book Value Ratio kinetabio.com|KA - Total Business Assets
- debt and liquidity data:
Debt to Equity Kineta, Inc.|KA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Kineta Bio|KA - Company Total Indebtedness|Debt to Book Value Kineta, Inc.|KA - Amount of Long-Term Liabilities|Company Short-Term Debts Kineta|Quick Ratio kinetabio.com
- earnings and valuation multiples indicators:
KA - Company Net Income|Expected Profit Kineta, Inc.|KA - Company Value to Net Income|Forward P/E Multiple Kineta|KA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kineta, Inc.|KA - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Kineta|KA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months kinetabio.com|KA - Earnings growth in current year|Earnings growth forecast for next year Kineta, Inc.
Comprehensive company analysis:Kineta, Inc. - KA
Mass-produced product of Kineta Corp

A portfolio analyst uses this tool to filter for the most resilient companies in the sector. The eps_ttm_co metric measures net income per share over the year, reflecting the actual return on equity. The current value of -1.64 confirms a deep crisis at Kineta, Inc. (KA) due to the cessation of development and workforce reductions. Negative momentum in the annual net income per share chart signals a critical risk of business liquidation.

Who Kineta, Inc. competes with

IBRX - Earnings per share for the last twelve months|immunocore.com (IMCR) - Net earnings per share for the last 12 months|Janux Therapeutics, Inc. (JANX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Arcus Biosciences Inc|Net earnings per share for the last 12 months ZYME|Net earnings per share (EPS TTM) Tango Therapeutics Corp|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|immatics.com - Earnings per share for the last 12 months|Earnings per share for the last twelve months Xencor XNCR|Compass Therapeutics Inc (CMPX) - Net earnings per one share for the last twelve months|REPL: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Lyell Pharma (LYEL)|IPHA (Innate Pharma S.A.) - Net earnings per share for the last 12 months|PYXS: Earnings per share for the last four quarters|CGEN (Compugen Ltd) - Net earnings per share (EPS TTM)|IOBT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) STRO|INKT - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Werewolf Therapeutics, Inc. HOWL|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|CUE - Net earnings per share (EPS TTM)|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months SONN (Sonnet BioTherapeutics Holdings)|Net earnings per share for the last 12 months MAIA|Net earnings per one share for the last twelve months liminatuspharma.com LIMN|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|Net earnings per share (EPS TTM) NextCure Inc (NXTC)|Net earnings per share (EPS TTM) LPTX (Leap Therapeutics)|Net earnings per share for the last four quarters Intensity Therapeutics Inc (INTS)|SNSE - Earnings per share for the last twelve months|TOVX (therivabio.com) - Earnings per share for the last 12 months|GRTS: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune Inc (NEXI)|Net earnings per share for the last 12 months TSBX|VCNX (Vaccinex Inc) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) HARP